赛诺菲喜保宁多少钱？

(Vigabatrin tablets) is the first new anti-epileptic drug developed and designed based on the pathophysiological mechanism of the disease. Based on the understanding of the relationship between the GABA neurotransmitter system and the onset of epilepsy, scientists have synthesized vigabatrin, which has a chemical structure very similar to the natural neurotransmitter GABA. The intention is to make this compound compete with GABA, inhibit the GABA aminotransferase, delay the metabolism of GABA, increase GABAergic neurotransmission and its mediated neural inhibition, and achieve the effect of inhibiting epileptic seizures.

Vigabatrin was first synthesized in 1974 and entered the clinical development stage for registration purposes in the 1970s. It was first approved for marketing in the UK in 1989. In the following years, the drug was widely used in various European countries, with an average of more than 38 prescriptions per day in the past 10 years, and it has significant anti-epileptic effects. So, how much does Sanofi Vigabatrin cost?

So far, France's Sanofi Vigabatrin has been launched in many countries and regions. Due to different pricing standards and medical insurance policies in each country, its final selling price is also different. According to Medical Companion Travel, a box of the Turkish version of Vigabatrin exported by France's Sanofi is priced at around $1,500. The drug specification is 500 mg x 100 capsules per box. It is a cost-effective drug currently on the market. Domestic patients in need can either go abroad to purchase local medicines in person, or contact some professional and formal overseas medical service organizations in China (such as Medical Companion Travel) to obtain purchase channels for the required medicines.

Sanofi is a world-leading diversified pharmaceutical and health company that focuses on patient needs and spreads health. The quality of its drugs is guaranteed and worthy of patients' trust. The medicine produced by it not only has remarkable efficacy, but also the price is relatively within the affordable range of patients. Since the medicine has not yet been approved by the National Medical Products Administration (NMPA) to be officially launched in China, patients in need can only choose to purchase medicine overseas first.

Recommended hot articles: /newsDetail/93753.html